AcuraStem

AcuraStem AcuraStem is a near-to-clinic, patient-based therapeutics company advancing treatments for ALS, FTD and additional neurodegenerative indications.

AcuraStem harnesses advanced cellular reprogramming and artificial intelligence technologies to transform the standard of care for neurodegenerative diseases through patient-specific treatment. Go to acurastem.com to find out more.

10/06/2025

Most neurodegenerative research still starts in models that don’t reflect the biology of the people they’re meant to help.

At AcuraStem, we take a different approach. Our iNeuroRX® platform uses patient-derived neurons to identify therapies grounded in human biology from the outset.

That means fewer dead ends, and more meaningful progress for ALS and other neurodegenerative diseases. Meet us at the 2025 NEALS Consortium Meeting in Clearwater, FL, October 7 - 10.

AcuraStem CEO Sam Alworth will be on-site and ready to connect.

Find out more at acurastem.com

AcuraStem at Pre-SPARKTomorrow AcuraStem co-founders Sam Alworth and Dr. Justin Ichida will speak on the Faculty Spinout...
08/26/2025

AcuraStem at Pre-SPARK

Tomorrow AcuraStem co-founders Sam Alworth and Dr. Justin Ichida will speak on the Faculty Spinout Panel at USC’s Pre-SPARK program, highlighting how academic breakthroughs can advance toward clinical application.

The panel is part of Pre-SPARK’s mission to support researchers navigating the complex path from lab discovery to therapeutic development, bringing together USC, CHLA, and industry experts to remove barriers to commercialization.

🧬 August 27 | 3–5 PM
📍 MCB 101, USC
🔗 https://sites.usc.edu/transformativedelivery/usc-spark

07/22/2025

📅 TODAY!: Don’t miss Sam Alworth, AcuraStem’s CEO, presenting “Using the iNeuroRX® Technology Platform to Develop Disease-Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS-241” at Frontiers in Neuroscience: Emerging Biology and Therapeutics, a free virtual symposium.

💻 Catch the talk Today at 11:20–11:55 AM PT via Zoom. Registration is free and open now. 🔗 There's still time to Register here 👇 :

https://lnkd.in/e9Q5ik4e

🧠 Sam will highlight how AcuraStem’s iNeuroRX® platform enables the discovery of potent, durable, and well-tolerated A*O drug candidates by modeling ALS and FTD using patient-derived cells, with a focus on AS-241, a promising UNC13A-targeting therapy.

















*O











07/18/2025

📆 Next week: Don’t miss Sam Alworth, AcuraStem’s CEO, presenting “Using the iNeuroRX® Technology Platform to Develop Disease-Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS-241” at Frontiers in Neuroscience: Emerging Biology and Therapeutics, a free virtual symposium.

🧠Sam will highlight how AcuraStem’s iNeuroRX® platform enables the discovery of potent, durable, and well-tolerated A*O drug candidates by modeling ALS and FTD using patient-derived cells, with a focus on AS-241, a promising UNC13A-targeting therapy.

💻Catch the talk on July 22 at 11:20–11:55 AM PT via Zoom. Registration is free and open now.
🔗 Register here: https://us02web.zoom.us/webinar/register/5717454312867/WN_h4EJml7FSL68V_hsT2QeIA








*O





07/16/2025

Many drug treatments fail because they rely on animal models that don’t fully capture human disease. At AcuraStem, we lead the way in creating patient-based models that accurately reflect neurodegenerative disease processes, bringing us closer to real solutions.

Learn more at 👉 acurastem.com




07/03/2025

Behind every breakthrough is a team of passionate scientists, researchers, and innovators. Get to know the people behind our life-changing drug discovery team at ➡️ pxl.to/AcuraStem







06/09/2025

Many drug treatments fail because they rely on animal models that don’t fully capture human disease. At AcuraStem, we lead the way in creating patient-based models that accurately reflect neurodegenerative disease processes, bringing us closer to real solutions.

Learn more: acurastem.com





05/31/2025

ALS Awareness Month may be ending…but diseases don’t follow calendars.

Awareness is just the beginning, real change comes through action, advocacy, and innovation.

Learn how we’re working toward transformative treatments for ALS at: http://acurastem.com




05/21/2025

ALS is the fastest-progressing neurodegenerative disease affecting 30,000 Americans. Despite its rapid progression, treatment options remain limited. At AcuraStem, we’re continuously working toward real solutions.
Discover our approach: acurastem.com


Disease

05/15/2025

📆: Next week: Don’t miss Wen-Hsuan Chang, AcuraStem’s AVP of Discovery and Early Development, presenting “Using the iNeuroRX® Technology Platform to Develop Disease-Modifying Treatments for ALS and FTD” at TIDES USA 2025, May 19–22 in San Diego.

Wen will share how AcuraStem’s iNeuroRX® platform leverages patient-derived cell models to capture the genetic and clinical diversity of ALS and FTD, enabling the discovery of highly potent, durable, and well-tolerated antisense oligonucleotide (A*O) drug candidates.

Don't miss this opportunity to connect with Wen and learn about AcuraStem's latest research and our expanding pipeline of antisense oligonucleotide therapies.

Learn more at 👉 https://pxl.to/TIDES

05/08/2025

📆 Next week: AcuraStem's CSO, Marcel van der Brug, will be presenting “Embracing Heterogeneity in ALS to Develop Diverse In Vitro Models that can Support Development of Targeted Therapeutics” at the 4th Annual ALS Drug Development Summit, scheduled for May 12–14, 2025, in Boston.

The ALS Drug Development Summit is a premier event that unites leaders from pharma, biotech, academia, and patient advocacy to drive advancements in ALS therapeutics.

Don't miss this opportunity to connect with Marcel and learn about AcuraStem's latest research, including our best-in-class iNeuroRX® technology platform, our expanding pipeline of antisense oligonucleotide therapies, and our focus on targeted treatment strategies for ALS.
🔗 Learn more at: https://www.als-drug-development.com/

05/07/2025

Many drug treatments fail because they rely on animal models that don’t fully capture human disease. At AcuraStem, we lead the way in creating patient-based models that accurately reflect neurodegenerative disease processes, bringing us closer to real solutions.

Learn more: acurastem.com




Address

605 E Huntington Drive
Monrovia, CA
91016

Website

Alerts

Be the first to know and let us send you an email when AcuraStem posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to AcuraStem:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram